Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Press Releases
Written By Thryv Therapeutics

  • Thryv Therapeutics to present virtually at Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28th from 2:15-2:45 p.m. ET.

Montreal, Quebec – February 20, 2024 – Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28th and 29th, 2024. Thryv’s virtual presentation will be on February 28th from 2:15-2:45 p.m. ET.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

Media Inquiries

daphne@thryvtrx.com | 514 973 0915

Thryv Therapeutics
Previous

Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024
Next

2023 Year End Report